KR960015399B1 - 면역 글로불린의 정제방법 - Google Patents

면역 글로불린의 정제방법 Download PDF

Info

Publication number
KR960015399B1
KR960015399B1 KR1019920701427A KR920701427A KR960015399B1 KR 960015399 B1 KR960015399 B1 KR 960015399B1 KR 1019920701427 A KR1019920701427 A KR 1019920701427A KR 920701427 A KR920701427 A KR 920701427A KR 960015399 B1 KR960015399 B1 KR 960015399B1
Authority
KR
South Korea
Prior art keywords
antibody
column
protein
compass
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019920701427A
Other languages
English (en)
Korean (ko)
Other versions
KR920703108A (ko
Inventor
얀 니콜라스 라마지 폴
알렌 제프리
Original Assignee
더 웰컴 파운데이션 리미티드
엘. 디. 젠킨스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR960015399(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 웰컴 파운데이션 리미티드, 엘. 디. 젠킨스 filed Critical 더 웰컴 파운데이션 리미티드
Publication of KR920703108A publication Critical patent/KR920703108A/ko
Application granted granted Critical
Publication of KR960015399B1 publication Critical patent/KR960015399B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019920701427A 1990-10-17 1991-10-17 면역 글로불린의 정제방법 Expired - Lifetime KR960015399B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9022547.5 1990-10-17
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin
PCT/GB1991/001816 WO1992007084A1 (en) 1990-10-17 1991-10-17 Purified cdw52-specific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702699A Division KR100193314B1 (ko) 1990-10-17 1992-10-30 정제된 면역 글로불린

Publications (2)

Publication Number Publication Date
KR920703108A KR920703108A (ko) 1992-12-17
KR960015399B1 true KR960015399B1 (ko) 1996-11-13

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019920701427A Expired - Lifetime KR960015399B1 (ko) 1990-10-17 1991-10-17 면역 글로불린의 정제방법
KR1019920702699A Expired - Lifetime KR100193314B1 (ko) 1990-10-17 1992-10-30 정제된 면역 글로불린

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019920702699A Expired - Lifetime KR100193314B1 (ko) 1990-10-17 1992-10-30 정제된 면역 글로불린

Country Status (29)

Country Link
US (1) US5644036A (cg-RX-API-DMAC7.html)
EP (1) EP0504363B2 (cg-RX-API-DMAC7.html)
JP (1) JP2638680B2 (cg-RX-API-DMAC7.html)
KR (2) KR960015399B1 (cg-RX-API-DMAC7.html)
AT (2) ATA900791A (cg-RX-API-DMAC7.html)
AU (3) AU658926B2 (cg-RX-API-DMAC7.html)
BE (1) BE1004226A5 (cg-RX-API-DMAC7.html)
BR (1) BR1100358A (cg-RX-API-DMAC7.html)
CA (1) CA2069481C (cg-RX-API-DMAC7.html)
CH (2) CH681305A5 (cg-RX-API-DMAC7.html)
DE (1) DE69128774T3 (cg-RX-API-DMAC7.html)
DK (1) DK0504363T4 (cg-RX-API-DMAC7.html)
ES (2) ES2112865T5 (cg-RX-API-DMAC7.html)
FI (2) FI110003B (cg-RX-API-DMAC7.html)
FR (2) FR2668164A1 (cg-RX-API-DMAC7.html)
GB (2) GB9022547D0 (cg-RX-API-DMAC7.html)
GR (3) GR910100425A (cg-RX-API-DMAC7.html)
HU (1) HUT64601A (cg-RX-API-DMAC7.html)
IE (1) IE913560A1 (cg-RX-API-DMAC7.html)
IL (3) IL99761A0 (cg-RX-API-DMAC7.html)
IT (1) IT1250064B (cg-RX-API-DMAC7.html)
LU (1) LU88122A1 (cg-RX-API-DMAC7.html)
MX (1) MX9203794A (cg-RX-API-DMAC7.html)
MY (2) MY136210A (cg-RX-API-DMAC7.html)
NZ (2) NZ244114A (cg-RX-API-DMAC7.html)
PT (2) PT99248B (cg-RX-API-DMAC7.html)
TW (1) TW283710B (cg-RX-API-DMAC7.html)
WO (1) WO1992007084A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA918259B (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
IL103418A (en) * 1991-10-15 1997-11-20 Wellcome Found Therapeutic agent for the t-cell mediated inflammation of the joints and its production
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
CN1122531C (zh) † 1995-08-01 2003-10-01 巴斯德梅诺血清和疫苗公司 抗日本脑炎疫苗的工业生产方法和所获得的疫苗
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
WO2002072615A1 (en) * 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
ES2321539T3 (es) * 2001-06-05 2009-06-08 Genetics Institute, Llc Procedimientos relativos a la purificacion de proteinas altamente anionicas.
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
BRPI0417993A (pt) * 2003-12-22 2007-04-27 Genzyme Corp anticorpo anti-cd52 para tratamento da diabetes
EP1869065B1 (en) * 2005-03-11 2020-05-06 Wyeth LLC A method of weak partitioning chromatography
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
NZ621170A (en) 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
EP3345620B1 (en) 2009-05-13 2024-08-28 Genzyme Corporation Methods and compositions for treating lupus
EP2519536A4 (en) * 2009-12-29 2013-06-05 Reddys Lab Ltd Dr PROTEIN PURIFICATION BY ION EXCHANGE
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
MX2016008498A (es) 2013-12-27 2016-10-07 Chugai Pharmaceutical Co Ltd Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3031028C (en) 2016-07-25 2024-02-13 Lu Wang Affinity chromatography wash buffer
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
US20220177518A1 (en) 2019-03-29 2022-06-09 Asahi Kasei Medical Co., Ltd. Method for purifying protein
CN113692420B (zh) 2019-04-08 2023-09-12 旭化成医疗株式会社 用于纯化含蛋白质的溶液的聚酰胺介质及其制造方法
US20220213140A1 (en) 2019-04-10 2022-07-07 Chugai Seiyaku Kabushiki Kaisha Method for purifying fc region-modified antibody
JPWO2022260091A1 (cg-RX-API-DMAC7.html) 2021-06-10 2022-12-15

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
JP3121823B2 (ja) * 1988-02-12 2001-01-09 ビーティージー・インターナショナル・リミテッド 抗体におけるまたは抗体に関する改良

Also Published As

Publication number Publication date
ZA918259B (en) 1993-04-16
AU658926B2 (en) 1995-05-04
JPH05504579A (ja) 1993-07-15
JP2638680B2 (ja) 1997-08-06
CH681305A5 (cg-RX-API-DMAC7.html) 1993-02-26
CA2069481C (en) 2003-07-29
EP0504363B1 (en) 1998-01-21
PT100988B (pt) 1999-08-31
AU4521897A (en) 1998-02-12
MY119030A (en) 2005-03-31
ITRM910788A1 (it) 1993-04-16
PT99248B (pt) 1999-04-30
ZA926191B (en) 1993-04-16
FI110003B (fi) 2002-11-15
PT99248A (pt) 1993-06-30
GR910100425A (el) 1992-09-25
PT100988A (pt) 1994-02-28
ATE162552T1 (de) 1998-02-15
BE1004226A5 (fr) 1992-10-13
ITRM910788A0 (it) 1991-10-16
GR920100471A (el) 1994-06-30
GR3026588T3 (en) 1998-07-31
DE69128774T2 (de) 1998-06-04
HU9202000D0 (en) 1992-10-28
FI110002B (fi) 2002-11-15
AU7024294A (en) 1995-01-05
FR2677997A1 (fr) 1992-12-24
FI922380L (fi) 1992-05-25
CA2069481A1 (en) 1992-04-18
IL102726A (en) 2002-08-14
GB2253397A (en) 1992-09-09
NZ244114A (en) 1995-06-27
BR1100358A (pt) 2000-03-28
CH681455A5 (cg-RX-API-DMAC7.html) 1993-03-31
IT1250064B (it) 1995-03-30
AU2532192A (en) 1993-02-11
IE913560A1 (en) 1992-04-22
AU649078B2 (en) 1994-05-12
TW283710B (cg-RX-API-DMAC7.html) 1996-08-21
WO1992007084A1 (en) 1992-04-30
DK0504363T3 (da) 1998-09-21
KR920703108A (ko) 1992-12-17
DK0504363T4 (da) 2007-05-29
LU88122A1 (fr) 1993-03-15
AU8729491A (en) 1992-05-20
DE69128774T3 (de) 2007-08-16
NZ240247A (en) 1994-03-25
DE69128774D1 (de) 1998-02-26
ATA900791A (de) 1996-06-15
HUT64601A (en) 1994-01-28
FR2668164B1 (cg-RX-API-DMAC7.html) 1995-04-14
FR2668164A1 (fr) 1992-04-24
ES2081742B1 (es) 1996-10-01
EP0504363B2 (en) 2007-02-07
FI922824L (fi) 1992-06-17
GB9022547D0 (en) 1990-11-28
IL102726A0 (en) 1993-01-31
FI922380A0 (fi) 1992-05-25
US5644036A (en) 1997-07-01
ES2081742A1 (es) 1996-03-01
ES2112865T5 (es) 2007-09-16
IL99761A0 (en) 1992-08-18
KR100193314B1 (ko) 1999-06-15
AU716402B2 (en) 2000-02-24
MX9203794A (es) 1992-07-01
ES2112865T3 (es) 1998-04-16
MY136210A (en) 2008-08-29
FI922824A0 (fi) 1992-06-17
GB9209529D0 (en) 1992-07-01
EP0504363A1 (en) 1992-09-23

Similar Documents

Publication Publication Date Title
KR960015399B1 (ko) 면역 글로불린의 정제방법
IE84931B1 (en) Purified IgG Antibodies
DE69130912T2 (de) Antikörperherstellung
KR102578087B1 (ko) 숙주세포 갈렉틴(galectins) 및 다른 오염물(contaminant)로부터 글리코실화 단백질을 정제하는 방법
CN116547298A (zh) 猫抗体恒定区中的突变
AU649078C (en) Purified CDW52-specific antibodies
WO1994015950A1 (en) Purification of immunoglobulin
CN119751679A (zh) 一种抗人cd13的抗体及其相关生产方法和应用
dos Santos An alternative capture step for monoclonal antibodies: phenylboronate as a new multi-modal ligand

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920616

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19921030

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920616

Comment text: Patent Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950830

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19960406

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19950830

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Appeal kind category: Appeal against decision to decline refusal

Decision date: 19970117

Appeal identifier: 1996201001015

Request date: 19960508

PB0901 Examination by re-examination before a trial

Comment text: Request for Trial against Decision on Refusal

Patent event date: 19960513

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 19960130

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19921030

Patent event code: PB09011R02I

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19961017

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 19970117

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 19960920

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19970408

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19970408

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 19991026

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20001108

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20011107

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20021107

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20031015

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20041011

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20051007

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20061013

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20071005

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20081007

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20091012

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20101029

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20101029

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term